Skip to main content

Humanigen Inc. (HGEN)

NASDAQ: HGEN · Delayed Price · USD
6.53
-0.30 (-4.39%)
Pre-market:Sep 20, 2021 7:50 AM EDT
6.83
0.17 (2.55%)
At close: Sep 17, 4:00 PM
Market Cap405.75M
Revenue (ttm)1.83M
Net Income (ttm)-199.42M
Shares Out58.84M
EPS (ttm)-3.87
PE Ration/a
Forward PE9.39
Dividendn/a
Ex-Dividend Daten/a
Volume3,580,548
Open6.70
Previous Close6.66
Day's Range6.39 - 6.86
52-Week Range6.03 - 29.20
Beta-2.38
AnalystsBuy
Price Target21.71 (+217.9%)
Est. Earnings DateNov 9, 2021

About HGEN

Humanigen, Inc., a clinical stage biopharmaceutical company, develops a portfolio of immuno-oncology and immunology monoclonal antibodies in the United States. The company's lead product candidate is Lenzilumab, a monoclonal antibody that targets and neutralizes human granulocyte-macrophage colony-stimulating factor, which is in Phase III clinical trial for the treatment of cytokine storm associated with COVID-19; and Phase Ib/II clinical trial as a sequenced therapy in combination with CD19 targeted chimeric antigen receptor T-cell therapies t...

IndustryBiotechnology
IPO DateJan 31, 2013
CEOCameron Durrant
Employees10
Stock ExchangeNASDAQ
Ticker SymbolHGEN
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 6 analysts, the average rating for Humanigen stock is "Buy." The 12-month stock price forecast is 21.71, which is an increase of 217.86% from the latest price.

Price Target
$21.71
(217.86% upside)
Analyst Consensus: Buy

News

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Humanigen, Inc. - HGEN

NEW YORK, Sept. 20, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Humanigen, Inc. ("Humanigen" or the "Company") (NASDAQ: HGEN).

7 hours ago - PRNewsWire

Humanigen Announces Participation and Presentation at Multiple Conferences in September

BURLINGAME, Calif.--(BUSINESS WIRE)--Humanigen, Inc. (Nasdaq: HGEN) (“Humanigen”), a clinical-stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine...

5 days ago - Business Wire

New Strong Sell Stocks for September 14th

ATR, FTAI, HGEN, LMB, and MRSN have been added to the Zacks Rank #5 (Strong Sell) List on September 14, 2021.

Other symbols:ATRFTAILMBMRSN
5 days ago - Zacks Investment Research

Why Humanigen Stock Is Sinking Today

The Food and Drug Administration turned down Emergency Use Authorization of lenzilumab in treating hospitalized COVID-19 patients.

1 week ago - The Motley Fool

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Humanigen, Inc. - HGEN

NEW YORK , Sept. 9, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Humanigen, Inc. (" Humanigen " or the "Company") (NASDAQ: HGEN).

1 week ago - PRNewsWire

After FDA Rejection This Biopharma Stock Garners Analyst Downgrades, Price Cuts

JPMorgan has downgraded Humanigen Inc (NASDAQ:HGEN) to Underweight from Neutral and withdrew its price target after the FDA rejected its Emergency Use request for lenzilumab for hospitalized COVID-19 pa...

1 week ago - Benzinga

Why Did Humanigen's Stock Dump Today And What's Next?

Humanigen Inc. (NASDAQ:HGEN) shares are trading sharply lower Thursday after the company announced the FDA declined its EUA request for lenzilumab in hospitalized COVID-19 patients. Humanigen was down 5...

1 week ago - Benzinga

Here's Why Humanigen Is Getting Hammered Today

An attempt to earn authorization for lenzilumab hit a wall at the FDA.

1 week ago - The Motley Fool

See Why Humanigen Stock Is Plunging To 52-Week Low

The FDA declined Humanigen Inc's (NASDAQ: HGEN) request for emergency use authorization (EUA) of its lenzilumab drug to treat newly hospitalized COVID-19 patients. The Company filed its application with...

1 week ago - Benzinga

FDA has declined Humanigen's Emergency Use Authorization (EUA) Request for Lenzilumab in Hospitalized COVID-19 Patients

BURLINGAME, Calif.--(BUSINESS WIRE)--Humanigen, Inc. (Nasdaq: HGEN) (“Humanigen”), a clinical-stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine...

1 week ago - Business Wire

Implied Volatility Surging for Humanigen (HGEN) Stock Options

Investors need to pay close attention to Humanigen (HGEN) stock based on the movements in the options market lately.

3 weeks ago - Zacks Investment Research

KaloBios Pharmaceuticals Inc. (HGEN) Reports Q2 Loss, Misses Revenue Estimates

KaloBios Pharmaceuticals Inc. (HGEN) delivered earnings and revenue surprises of -160.87% and -98.27%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the...

1 month ago - Zacks Investment Research

Humanigen Reports Second Quarter 2021 Financial Results

BURLINGAME, Calif.--(BUSINESS WIRE)--Humanigen, Inc. (Nasdaq: HGEN) (“Humanigen”), a clinical stage biopharmaceutical company focused on preventing and treating an immune hyper-response called “cytokine...

1 month ago - Business Wire

Humanigen's COVID-19 Candidate Shows 2.5 Fold Increase In Survival Without Ventilation

Humanigen Inc (NASDAQ: HGEN) has announced an analysis of results from its Phase 3 LIVE-AIR study of lenzilumab in hospitalized patients with COVID-19. Data suggested that Black and African-American pat...

1 month ago - Benzinga

Lenzilumab Treatment May Provide Enhanced Likelihood of Survival Without Ventilation in Hospitalized Black and Africa...

BURLINGAME, Calif.--(BUSINESS WIRE)--Lenzilumab Treatment May Provide Enhanced Likelihood of Survival Without Ventilation in Hospitalized Black and African-American COVID-19 Patients

1 month ago - Business Wire

NIH Advances ACTIV-5/BET-B Trial Evaluating Lenzilumab from a Phase 2 Exploratory Study to a Phase 2/3 Study for the ...

BURLINGAME, Calif.--(BUSINESS WIRE)--NIH Advances ACTIV-5/BET-B study to a Phase 2/3 study and modified the primary endpoint to survival without ventilation

1 month ago - Business Wire

Humanigen's Partner in South Korea Receives Ministry of Food and Drug Safety (MFDS) Approval to Conduct Phase 1 Study...

BURLINGAME, Calif.--(BUSINESS WIRE)--Humanigen, Inc. (Nasdaq: HGEN) (“Humanigen”), today announced its development and commercialization partners for South Korea and the Philippines, Telcon RF Pharmaceu...

1 month ago - Business Wire

Is the Options Market Predicting a Spike in Humanigen (HGEN) Stock?

Investors need to pay close attention to Humanigen (HGEN) stock based on the movements in the options market lately.

2 months ago - Zacks Investment Research

UK's MHRA accepts Humanigen's submission of Lenzilumab for Marketing Authorization in COVID-19 for expedited rolling ...

BURLINGAME, Calif.--(BUSINESS WIRE)--UK's MHRA accepts Humanigen's submission of Lenzilumab for Marketing Authorization in COVID-19 for expedited rolling review

2 months ago - Business Wire

Humanigen Inc. Added to Russell 3000(R) Index

Burlingame, California--(Newsfile Corp. - June 28, 2021) - Humanigen, Inc. (NASDAQ: HGEN) ("Humanigen"), a clinical-stage biopharmaceutical company focused on preventing and treating an immune hyper-res...

2 months ago - Newsfile Corp

Humanigen Initiates Submission for Lenzilumab Marketing Authorization in COVID-19, to the United Kingdom's Medicines ...

BURLINGAME, Calif.--(BUSINESS WIRE)--Humanigen announced it has initiated a rolling review submission for Marketing Authorization (MA) by the MHRA for its lead drug candidate, lenzilumab

3 months ago - Business Wire

Why This COVID-19 Stock Is On Fire Right Now

While vaccines and diagnostics have been the big winners in the space so far, Humanigen might make investors a lot of money with its drug to treat cytokine storms caused by COVID-19.

Other symbols:GSKNVAX
3 months ago - The Motley Fool

Humanigen Announces Ken Trbovich Appointed as Senior Vice President, Investor Relations

BURLINGAME, Calif.--(BUSINESS WIRE)--Humanigen, Inc. (Nasdaq: HGEN) (“Humanigen”), a clinical-stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine...

3 months ago - Business Wire

Humanigen to Present at the 2021 LD Micro Invitational XI

BURLINGAME, Calif.--(BUSINESS WIRE)--Humanigen announces it will present at the 2021 LD Micro Invitational XI

3 months ago - Business Wire

2 Top Biotech Stocks to Buy Right Now

One is growing revenue. And the other may soon launch its first product.

Other symbols:EXEL
3 months ago - The Motley Fool